Literature DB >> 27164301

Current challenges and emerging drug delivery strategies for the treatment of psoriasis.

Melissa B Hoffman1, Dane Hill1, Steven R Feldman1,2,3.   

Abstract

INTRODUCTION: Psoriasis is a common skin disorder associated with physical, social, psychological and financial burden. Over the past two decades, advances in our understanding of pathogenesis and increased appreciation for the multifaceted burden of psoriasis has led to new treatment development and better patient outcomes. Yet, surveys demonstrate that many psoriasis patients are either undertreated or are dissatisfied with treatment. There are many barriers that need be overcome to optimize patient outcomes and satisfaction. AREAS COVERED: This review covers the current challenges associated with each major psoriasis treatment strategy (topical, phototherapy, oral medications and biologics). It also reviews the challenges associated with the psychosocial aspects of the disease and how they affect treatment outcomes. Patient adherence, inconvenience, high costs, and drug toxicities are all discussed. Then, we review the emerging drug delivery strategies in topical, oral, and biologic therapy. EXPERT OPINION: By outlining current treatment challenges and emerging drug delivery strategies, we hope to highlight the deficits in psoriasis treatment and strategies for how to overcome them. Regardless of disease severity, clinicians should use a patient-centered approach. In all cases, we need to balance patients' psychosocial needs, treatment costs, convenience, and effectiveness with patients' preferences in order to optimize treatment outcomes.

Entities:  

Keywords:  Treatment adherence; biologics; biosimilars; compliance; phototherapy; small molecule agents; systemics

Mesh:

Substances:

Year:  2016        PMID: 27164301     DOI: 10.1080/17425247.2016.1188801

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  7 in total

1.  Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis.

Authors:  J Niu; Z Zhai; F Hao; Y Zhang; Z Song; H Zhong
Journal:  Clin Exp Immunol       Date:  2018-03-06       Impact factor: 4.330

2.  Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities.

Authors:  Tao Wan; Wenhui Pan; Yueming Long; Kaiyue Yu; Sibo Liu; Wenyi Ruan; Jingtong Pan; Mengyao Qin; Chuanbin Wu; Yuehong Xu
Journal:  Int J Nanomedicine       Date:  2017-02-22

3.  Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats.

Authors:  Md Khalid Anwer; Muqtader Mohammad; Essam Ezzeldin; Farhat Fatima; Ahmed Alalaiwe; Muzaffar Iqbal
Journal:  Int J Nanomedicine       Date:  2019-03-01

4.  Patient and physician preferences for attributes of biologic medications for severe asthma.

Authors:  Heather L Gelhorn; Zaneta Balantac; Christopher S Ambrose; Yen N Chung; Brian Stone
Journal:  Patient Prefer Adherence       Date:  2019-07-25       Impact factor: 2.711

5.  Celastrol Niosome Hydrogel Has Anti-Inflammatory Effect on Skin Keratinocytes and Circulation without Systemic Drug Exposure in Psoriasis Mice.

Authors:  Fen Qiu; Long Xi; Shengshuang Chen; Yonghua Zhao; Zhenping Wang; Ying Zheng
Journal:  Int J Nanomedicine       Date:  2021-09-04

6.  Transdermal Delivery of Indirubin-Loaded Microemulsion Gel: Preparation, Characterization and Anti-Psoriatic Activity.

Authors:  Enxue He; Hailing Li; Xiaokun Li; Xunxun Wu; Kun Lei; Yong Diao
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 7.  Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.

Authors:  Ana M Martins; Andreia Ascenso; Helena Margarida Ribeiro; Joana Marto
Journal:  Mol Neurobiol       Date:  2020-02-15       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.